[go: up one dir, main page]

WO2008108927A3 - Methods and compositions for stabilizing polypeptides - Google Patents

Methods and compositions for stabilizing polypeptides Download PDF

Info

Publication number
WO2008108927A3
WO2008108927A3 PCT/US2008/002261 US2008002261W WO2008108927A3 WO 2008108927 A3 WO2008108927 A3 WO 2008108927A3 US 2008002261 W US2008002261 W US 2008002261W WO 2008108927 A3 WO2008108927 A3 WO 2008108927A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
stabilizing polypeptides
stabilizing
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/002261
Other languages
French (fr)
Other versions
WO2008108927A2 (en
Inventor
Gabriel Sosne
David Crockford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RegeneRx Biopharmaceuticals Inc
Original Assignee
RegeneRx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RegeneRx Biopharmaceuticals Inc filed Critical RegeneRx Biopharmaceuticals Inc
Publication of WO2008108927A2 publication Critical patent/WO2008108927A2/en
Publication of WO2008108927A3 publication Critical patent/WO2008108927A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method of stabilizing a polypeptide outside of a body by combining the polypeptide with an aqueous solution containing substantially physiological levels of electrolytes and salts.
PCT/US2008/002261 2007-03-06 2008-02-21 Methods and compositions for stabilizing polypeptides Ceased WO2008108927A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90505107P 2007-03-06 2007-03-06
US60/905,051 2007-03-06

Publications (2)

Publication Number Publication Date
WO2008108927A2 WO2008108927A2 (en) 2008-09-12
WO2008108927A3 true WO2008108927A3 (en) 2008-12-04

Family

ID=39738962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/002261 Ceased WO2008108927A2 (en) 2007-03-06 2008-02-21 Methods and compositions for stabilizing polypeptides

Country Status (1)

Country Link
WO (1) WO2008108927A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP3210614A4 (en) * 2014-10-22 2018-06-13 G-Treebnt Co., Ltd. Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
US9867868B2 (en) * 2015-08-18 2018-01-16 G-Treebnt Co., Ltd. Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid
US10744088B2 (en) * 2015-10-06 2020-08-18 G-Treebnt Co., Ltd. Method for preparing ophthalmic preparation containing thymosin beta-4
KR102115158B1 (en) * 2016-11-29 2020-05-26 주식회사 지트리파마슈티컬 Formulation comprising thymosin beta 4
KR102340750B1 (en) * 2017-03-03 2021-12-21 에이치엘비테라퓨틱스 주식회사 Stabilized topical composition comprising thymosin beta 4 as an active ingredient
IT201900000561A1 (en) * 2019-01-14 2020-07-14 Medivis S R L Chemically and physically stable topical ophthalmic formulations based on Nepafenac
GB201916379D0 (en) * 2019-11-11 2019-12-25 Biocrucible Ltd Biochemical reaction methods and reagents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHI E.Y. ET AL.: "Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation", PHARM. RES., vol. 20, no. 9, September 2003 (2003-09-01), pages 1325 - 1336, XP002475010 *
GOLDSTEIN A.L. ET AL.: "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues", TRENDS IN MOLECULAR MEDICINE, vol. 11, no. 9, September 2005 (2005-09-01), pages 421 - 429, XP005065335 *
PHILP D. ET AL.: "Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice in aged mice", WOUND REPAIR AND REGENERATION, vol. 11, no. 1, January 2003 (2003-01-01) - February 2003 (2003-02-01), pages 19 - 24, XP002441696 *
WANG W. ET AL.: "Antibody Structure, Instability, and Formulation", J. PHARM. SCI., vol. 96, no. 1, January 2007 (2007-01-01), pages 1 - 26, XP009084505 *

Also Published As

Publication number Publication date
WO2008108927A2 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
WO2008108927A3 (en) Methods and compositions for stabilizing polypeptides
NZ600330A (en) Device for hand disinfection
WO2012014074A3 (en) Motion compensation for non-invasive treatment therapies
WO2010120368A3 (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
MX2012004420A (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes.
WO2011143346A3 (en) Implant with deployable stabilizers
WO2007140440A3 (en) Polymerizable compositions containing salts of barbituric acid derivatives
WO2009020067A1 (en) Liquid cosmetic preparation
WO2008107568A3 (en) Method for preparing polyhydroxy-urethanes
UA115772C2 (en) Compositions and methods for modifying a predetermined target nucleic acid sequence
WO2007083108A3 (en) Implantable elongate member
TN2012000248A1 (en) Novel spiropiperidine compounds
WO2010107874A3 (en) Methods for affecting body composition using amylin agonists
IL221243A0 (en) Heterocyclic inhibitors of glutaminyl cyclase (qc,ec 2.3.2.5)
NZ607274A (en) High-protein beverages comprising whey protein
WO2012095667A3 (en) Improvements in coating technology
BRPI1007414A2 (en) thiadiazole and oxadiazole derivatives, their preparation and their application in therapeutic
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
WO2009117740A3 (en) Treatment of intervertebral disc degeneration
WO2009144551A3 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
WO2011051916A3 (en) Stabilized protein formulations and use thereof
EA201070194A1 (en) STABLE LIQUID PHARMACEUTICAL COMPOSITION BASED ON TRAZODONE
WO2011109418A3 (en) Apparatus for storage vessel deployment and method of making same
WO2012019689A3 (en) Use of hydroxypyridones or salts thereof for stabilizing hydrogen peroxide or hydrogen peroxide donor substances
EA201190256A1 (en) A METHOD FOR REDUCING THE LEVEL OF UBIVITILATED PROTEINS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08725854

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08725854

Country of ref document: EP

Kind code of ref document: A2